Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab + pyrotinib neoadjuvant therapy for HER2-positive early breast cancer (real-world)
ChiCTR2400090883Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab and pyrotinib in breast cancer, sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoint: Total pathological complete response rate (tpCR). Planned start Oct 2024; status: not yet recruiting.
02
Drugs
trastuzumabpyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400090883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090883.